title: Use of tenofovir disoproxil fumarate in highly viremic, hepatitis B mono-infected pregnant women.
abstract: BACKGROUND
  Antiviral therapy in addition to immunoprophylaxis at birth has been shown to further reduce perinatal transmission of hepatitis B virus (HBV) in highly viremic women.
  
  
  OBJECTIVE
  The aim of this study was to describe the use of tenofovir disoproxil fumarate (TDF) prophylaxis to reduce maternal HBV DNA levels and potentially vertical transmission in highly viremic women.
  
  
  METHODS
  After receiving IRB approval, we performed a retrospective chart review of mothers positive for hepatitis B surface antigen (HBsAg) who delivered between 2009 and 2012. We identified women with HBV DNA levels ≥6 log copies/mL who were treated with TDF in pregnancy.
  
  
  RESULTS
  There were 22 women identified. The majority were of Micronesian ethnicity. All were negative for hepatitis C antibody and HIV infection. The median gestational age of TDF initiation was 31 weeks with a median duration of treatment of 45 days. There was a reduction in median HBV DNA levels from baseline 9.0 ± 2.0 to 5.4 ± 1.1 log copies/mL after treatment. There were five (22.7 %) preterm deliveries and five (22.7 %) cesarean deliveries. All infants received immunoprophylaxis at birth. Postnatal HBsAg testing at 9-12 months was available for 13 infants, 12 of which were negative. There was one case of perinatal transmission.
  
  
  CONCLUSIONS
  This is the second published case series to date on the use of TDF prophylaxis in HBV mono-infected, highly viremic mothers. This series suggests the use of TDF in pregnancy reduces maternal HBV DNA levels and is well tolerated.
authors.affiliation: Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology, and Women's Health, John A. Burns School of Medicine, University of Hawaii, 1319 Punahou Street, Suite 824, Honolulu, HI, 96826, USA, paijong@hawaii.edu.
authors.forename: Pai-Jong Stacy
authors.initials: PJ
authors.lastname: Tsai
authors.forename: Ann
authors.initials: A
authors.lastname: Chang
authors.forename: Seiji
authors.initials: S
authors.lastname: Yamada
authors.forename: Naoky
authors.initials: N
authors.lastname: Tsai
authors.forename: Marguerite Lisa
authors.initials: ML
authors.lastname: Bartholomew
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood*; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy*; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D016017:Odds Ratio; D063065:Organophosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D011247:Pregnancy; D012307:Risk Factors; D000068698:Tenofovir; D014766:Viremia; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine